LP-0145 is under clinical development by Leo Pharma and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect LP-0145’s likelihood of approval (LoA) and phase transition for Atopic Dermatitis (Atopic Eczema) took place on 25 Oct 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their LP-0145 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
LP-0145 (ARGX-112) is under development for the treatment of atopic dermatitis. The drug candidate is a fully human monoclonal antibody which targets IL22R. The drug candidate is developed based on SIMPLE antibody platform and Nhance technologies. It is administered through subcutaneous route.
Leo Pharma overview
Leo Pharma, a subsidiary of LEO Foundation, is a drug manufacturing company. It discovers, develops, manufactures, and commercializes medicines for skin diseases and thrombosis. Its product portfolio spans pharmaceuticals for the treatment of diseases such as eczema, psoriasis, skin infections, actinic keratosis, non-melanoma skin cancer and thrombosis. The company also manufactures and markets products for the treatment of bacterial infections, coagulation, cardiovascular, antibiotics, nutritional disorders, osteoporosis, and renal problems. Leo Pharma markets its products worldwide. The company has a presence in Europe, the Middle East, Africa, Asia, the Americas, and Oceania. Leo Pharma is headquartered in Ballerup, Denmark.
Quick View LP-0145 LOA Data
|Highest Development Stage|